9.A.55.1.1
The cisplatin (Pt²⁺ coordinatioin complex/ Pt²⁺ drug complexes) exporter, TMEM205; DUF4149. Genetic polymorphisms may alter chemotheraputic responses in lung cancer patients. (Shen et al., 2010; Shen and Gottesman 2012; Wang et al. 2014).  The N- and C-termini may be extracellular (Attwood et al. 2016). Human TMEM205 mediates Pt(ii)-drug export selectively towards cisplatin and oxaliplatin but not carboplatin (Gallenito et al. 2020). By mutational analyses, they showed that hTMEM205 recognizes and allows Pt(ii)-extrusion by a putative sulfur-based translocation mechanism, thereby resulting in pre-target resistance. The small endosomal recycling GTPase, RAB8, plays a role in TMEM205-associated resistance to the chemotherapeutic drug cisplatin (Shen and Gottesman 2012). Cisplatin binding to the angiogenin protein provides a new molecular pathway and target for the drug's anticancer activity (Ferraro et al. 2023).